Research & Innovation
CHO PHARMA strives to develop state-of-the-art glycoengineering platform technologies to create new medicines with best-in-class efficacy. In addition, we focus our research efforts on new classes of immunotherapeutics targeting novel carbohydrate antigens.
-
Innovative glycoengineering technologies
-
SAR-based glycoengineered biobetters
-
Glycosite-specific antibody-drug conjugates (ADCs)
-
Novel antibodies and vaccines targeting novel carbohydrate antigens
-
Programs using our proprietary glycoengineering technologies
Rooted in glycoscience, we are dedicated to advancing a portfolio of :
CHOptimax™
CHOptimax™, Our Solution for Next-Generation Medicines
CHOptimax™ is a simple yet powerful in vitro enzymatic one-pot process that can efficiently convert naked antibodies into glycoengineered biobetter, or glycosite-specific antibody-drug conjugate (ADC).
Advantages of CHOptimax™
ONE-POT
REACTION
One-pot process requires only one enzyme & one substrate
ONE DAY
WORKING TIME
Scalable GMP process that can be completed within 24 hours
ONE WELL-DEFINED
STRUCTURE
Homogeneous product profile without compromising yield
Glycoengineered biobetter
Fine-Tune Biological Activity through Glycosylation
With the capability to precisely control the glycosylation profile of a given antibody, CHOptimax™ enables a glycan-based structure-activity relation (SAR) study to optimize its biological functions.
Our pioneering work has delivered CHO-H01, the world’s first glycoengineered antibody biobetter with a single optimized glycoform. Learn more about CHO-H01 .
Glycosite-specific ADC
One-Step from Naked Antibody to Best-in-Class ADC
With our proprietary donor substrates, CHOptimax™ enables one-step payload conjugation at the conserved Fc N-glycosylation site. The effector functions, such as ADCC, can be simultaneously enhanced via glycoengineering.
For customized linkers and/or payloads, CHOptimax™ provides antibodies with at least 4 functional groups available for glycosite-specific conjugation.
- Applicable to “off-the-shelf” antibodies - Free of production clone and upstream process re-development
- Free of structural alteration ‒ Fully natural structure without artificial amino acid/tag and structural reduction
- Cost- & time-effective ‒ One enzyme, one substrate, one step
- Painless CMC ‒ Glycosite-specific conjugation and homogeneous product profile
CHOptimax, the total solution for ADC manufacturing
|
CHOptimax™ |
Platform A |
Platform B |
Platform C |
Platform D |
|
|---|---|---|---|---|---|
|
Conjugation Site(s) |
Glycosite |
Glycosite |
Cysteine residue |
Artificial tag |
Unnatural amino acid or artificial tag |
|
“Off-the-shelf” Antibodies |
Applicable |
Applicable |
Applicable |
Not applicable |
Not applicable |
|
Structure Alteration |
No alteration |
No alteration |
Disulfide bond reduction |
Primary sequence |
Primary sequence |
|
Conjugation Method |
Enzymatic |
Enzymatic plus chemical |
Chemical |
Enzymatic |
Chemical |
|
Steps for Conjugation |
Single |
Multiple |
Multiple |
Single |
Single |
|
Enzyme(s) |
Single |
Multiple |
n.a. |
Single |
n.a. |
|
ADCC Enhancement |
Optional |
- |
|||
Patent
Patent Portfolios of CHOptimax™
60+ Granted & 20+ Pending Patents
Covering platform technologies, product compositions and proprietary enzymes.